NRX Pharmaceuticals, Inc.
For the period ended Mar 31, 2025. Filed May 15, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 15, 2025
What changed in Risk Factors?
Read the current filingPrevious report: 10-Q
Period ended 2024-09-30; filed 2024-11-14.
0001437749-24-035289
ITEM 1A. Risk FactorsCurrent report: 10-Q
Period ended 2025-03-31; filed 2025-05-15.
0001437749-25-017252
Item 1A. Risk FactorsThe baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.
Compared 2 previous paragraphs and 6 current paragraphs.
1 unchanged; 0 reworded; 5 added; 1 removed; 0 previous and 0 current paragraphs rearranged.
Tables are not compared: 0 previous and 0 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.
A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.
Added paragraphs (5)
Current report
No unregistered sales of equity securities occurred during the three months ended March 31, 2025, that were not previously reported.
Current report
No defaults upon senior securities occurred during the three months ended March 31, 2025, that were not previously reported.
Current report
None of our directors or executive officers adopted or terminated a Rule10b5-1 trading arrangement or a non-Rule10b5-1 trading arrangement during the quarter ended* March 31, 2025,as such terms are defined under Item408*(a) of Regulation S-K. Additionally, we didnot adopt or terminate a Rule10b5–1 trading arrangement during the quarter ended* March 31, 2025.*